Radboudumc
Nijmegen, Netherlands
NCT Number: NCT03298659
In patients with acute ST-elevation myocardial infarction (STEMI), 40-60% have multi-vessel disease with an increased cardiovascular morbidity and mortality. Although it is not recommended to revascularize noninfarct lesions during the acute intervention, recent investigations suggest the opposite and show improved outcome after direct revascularization of noninfarct lesions. It is undesirable to risk procedure-related complications by treating noninfarct lesions without impaired flow. It is currently unknown whether pressure guided revascularization of noninfarct lesions in the acute phase improves outcome compared to the current guidelines.
The iMODERN trial aims to compare an iFR-guided intervention of noninfarct lesions during the acute intervention with a deferred stress perfusion CMR-guided strategy during the outpatient follow-up, to determine the optimal therapeutic approach for STEMI patients with multivessel lesions.
This study is active but is not currently recruiting participants.
Notify Me18 year and older
All sexes
Interventional
Not applicable
Nijmegen, Netherlands
Study design:
The study is a prospective, randomized controlled, multicentre study.
Study population:
The research population will be recruited from the general patient population presenting with an acute STEMI. Patients treated with successful primary PCI and one or more additional significant coronary lesions in another coronary artery will be enrolled in the study. A total of 1,146 consecutive patients will be included.
Intervention:
The patients will be randomized 1:1, to (A) an active treatment arm with complete, iFR-guided revascularization of every noninfarct coronary lesion >50% and iFR ≤0.89; (B) a deferred treatment arm, in which patients will undergo an adenosine stress perfusion CMR scan within 6 weeks after STEMI, with revascularization of the noninfarct coronary lesions with associated perfusion defects.
Main study parameters/endpoints:
The primary end point consists of a combined outcome, including all-cause death, recurrent MI and hospitalization for heart failure at 3 years follow-up.
Duration:
Anticipated recruitment is 2 years. Follow-up will be performed at 6 months, 12 months, 3 years and 5 years.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Treatment guided by instantaneous wave-free ratio
Treatment guided by stress perfusion CMR
Time frame: 3 years
All-cause death, recurrent myocardial infarction and hospitalization for heart failure
Time frame: 6 months, 12 months, and 5 years
All-cause death, recurrent myocardial infarction and hospitalization for heart failure
Time frame: 6 months, 12 months, 3 years, and 5 years
Death from cardiovascular causes
Time frame: 6 months, 12 months, 3 years, and 5 years
Myocardial infarction
Time frame: 6 months, 12 months, 3 years, and 5 years
Stroke
Time frame: 6 months, 12 months, 3 years, and 5 years
TIA
Time frame: 6 months, 12 months, 3 years, and 5 years
Haemorrhagic complications
Time frame: 6 months, 12 months, 3 years, and 5 years
Unstable angina including ECG-changes
Time frame: 6 months, 12 months, 3 years, and 5 years
Any coronary artery revascularization
Time frame: 6 months, 12 months, 3 years, and 5 years
Coronary angiography
Time frame: 6 months, 12 months, 3 years, and 5 years
Stent thrombosis
Time frame: 6 months, 12 months, 3 years, and 5 years
Failure and/or revascularization by percutaneous or surgical methods of the target lesion, including cardiac death, MI, or clinically-driven target lesion revascularization
Time frame: 6 and 12 months, 3 and 5 years
Costs related to complete, iFR-guided revascularization versus CMR-guided treatment, including cost utility analysisfrom a societal perspective with the costs per prevented cardiac eventand the costs per QALY as the respective primary health economic outcomes (using a quality of life questionnaire and a health care resource use questionnaire)
Time frame: From enrolment to 6 and 12 months, 3 and 5 years follow-up
Quality of life is measured by standardized questionnaires, i.e. SAQ, EQ-5D-5L and Minnesota heart failure questionnaire, at 6 and 12 months, 3 and 5 years
Radboud University Medical Center
Other
Instantaneous Wave-free Ratio Guided Multi-vessel revascularizatiOn During Percutaneous Coronary intervEntion for Acute myocaRdial iNfarction (iMODERN)
Acronym: iMODERN
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05527717
Acute Myocardial Infarction, Cardiogenic Shock
Seoul, South Korea
View Trial DetailsNCT05800951
Acute Myocardial Infarction, Acute Myocardial Infarction With ST Elevation
Loma Linda, California, United States
View Trial DetailsNCT07522164
Acute Myocardial Infarction
Shanghai, China
View Trial DetailsNCT07367399
Acute Myocardial Infarction, Clinical Decision Support System
Beijing, China
View Trial Details